Jubilant Life Sciences Limited - jubl.com

1 Investor PresentationNovember 2020 Jubilant life Sciences LimitedDisclaimerImportantDisclaimerThis presentation(the Presentation ,orthe document )hasbeenpreparedbyJubilantLifeSciencesLi mited(the Company ) ,inwholeorinpart, ,reproduced,distributed,orotherwisediscl osedorpassedontoothers,inwholeorinpart,b yanymeans, ,neithertheCompany,noritsassociatesandaf filiates,noranyoftheirrespectiveofficers ,directors,advisors,undertakeanyobligati ontoprovidetotherecipient(a)accesstoanya dditionalinformationortoupdatethisdocume nt,or(b)

2 Forward-looking ,includingstatementsrelatingtofuturestat us,events,prospectsorcircumstances,inclu dingbutnotlimitedtostatementsaboutplansa ndobjectives,outlook,theprogressandresul tsofresearchanddevelopment,potentialprod uctcharacteristicsanduses, ,includingfuturechangesordevelopmentsint heCompany sbusiness,itscompetitiveenvironment,itsa bilitytoimplementitsstrategiesandinitiat ives,respondtoindustrychangesandthepolit ical,economic, ,fromtimetotime,makeadditionalwrittenand oralforwardlookingstatements,includingst atementscontainedinthecompany , ,offeringcircularorofferingmemorandumora nofferinvitationorasolicitationofanyoffe rtopurchaseorsell,anysecuritiesoftheComp any,andshouldnotbeconsideredorconstruedi nanymannerwhatsoeverasarecommendationtha tanypersonshouldsubscribefororpurchasean yofCompany' ,expectations,estimatesorprospectsinthis Presentationshouldbeconstruedasaforecast implyinganyindicativeassuranceorguarante eoffutureperformance,northattheassumptio nsonwhichsuchfutureprojections,expectati ons,estimates.

3 (includingbyopinion,anecdoteandspeculati on) ,noritsassociatesandaffiliates,noranyoft heirrespectiveofficers,directors,advisor s,makesanyrepresentationorwarranty(expre sslyorimpliedly)astotheaccuracy, , ,isnotarecommendationtoinvest,isnotaninv estmentadvice,and, ,theCompanyhavenottakenintoaccountthepar ticularinvestmentobjectives, ,aninvestorshouldindependentlyconsiderwh etheraninvestmentintheCompanyisappropria teinlightofitsparticularinvestmentneeds, , , ,andcomplywith, ,uponrequest, ,therecipientagreesthatthisPresentationi sstrictlyconfidentialandshallnotbecopied ,published,distributedortransmittedtoany person,inwholeorinpart,byanymeans.

4 Inanyformunderanycircumstanceswhatsoever andthattherecipienthasfurtheragreed,upon request, ,andthatitwillnotreproduce,publish,discl ose, , , ,areasperIndianAccountingStandards(Ind-A S) USD billion integrated global pharmaceuticals and life Sciences company Strong position in Specialty Pharmaceuticals Radiopharma and Allergy Therapy Products, CMO of sterile injectables 6 USFDA approved manufacturing facilitiesincluding 4 in North America and 2 in India; 5 state-of-the-art LSI mfg. facilities in India Expertise in chemistryand manufacturing spanning over four decades of experience; Offering 100+ Products; global leadership position in Pyridine-Beta and 11 Pyridine derivatives.

5 Globally Top 2 in Vitamin B3 and Acetic Anhydride (Merchant Sales) Employs over 8,000 people globally, including over 2,300 in North America and around 500 people dedicated to R&DSpecialty Pharmaceuticals33%CDMO17%Generics13%Spec ialty Intermediates12%Nutritional Products6% life Sciences Chemicals17%DDDS3% Jubilant life Sciences OverviewFY20 Revenue Mix by SegmentIndia22%USA & Canada56%Europe & Japan13%China and ROW9%FY20 Revenue Contribution by RegionFY20 EBITDA Mix by SegmentPharmaceuticalsSpecialty Pharmaceuticals Radiopharma Allergy Therapy ProductsDrug Discovery & Development Solutions ( Jubilant Biosys)

6 Generics2 Solid Dosage Formulations India Branded Pharmaceuticals (IBP)CDMO CMO of Sterile Injectablesand Non Sterile Products Active Pharmaceutical IngredientsProprietary Novel Drugs ( Jubilant Therapeutics) Discovery & Development Solutions business, earlier presented under segment Others has from Q2 FY20 onwards been reclassified under Pharmaceuticals segment within Generics subsegmentPharmaceuticals76% life Science Ingredients21%DDDS4%100% = Rs9,154 Cr100% = Rs9,154 Cr100% = Rs2,060 CrLife Science IngredientsSpecialty Intermediates Advanced Intermediates Specialty IngredientsNutritional Products Vitamins Animal Nutrition / Human NutritionLife Sciences Chemicals Acetyls Ethanol4 USFDA approved manufacturing facilities in North America and 2 USFDA approved manufacturing facilities in India.

7 5 state-of-the-art life Science Ingredients manufacturing facilities in IndiaPharmaceuticals Manufacturing FacilitiesLife Science Manufacturing FacilitiesSalisbury, Maryland, USA Solid Dosage Formulations (Tablets & Capsules)Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapyRoorkee, Uttarakhand Generics manufacturingGajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and life Science ChemicalsNira, Maharashtra life Sciences ChemicalsAmbarnath, Maharashtra Specialty IntermediatesBharuch, Gujarat SEZ for Vitamins ,Specialty Intermediates and LifeSciences ChemicalsSamlaya, Gujarat Animal Nutrition ProductsMontreal.

8 Canada Radiopharmaceuticals Contract Manufacturing of Sterile Injectablesand non-Sterile ProductsNanjangud, Karnataka API manufacturingNoida Corporate Office5 High-Quality, World-Class, Low Cost Manufacturing FootprintFacilityLast InspectionMontreal, CMOMay, 2018 Montreal, RadiopharmaSep, 2017 SalisburyFeb, 2020 SpokaneJuly, 2019 RoorkeeNov, 2019 NanjangudDec, 2018 ShyamS BhartiaChairman 39 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and ITHari S BhartiaCo-Chairman & Managing Director33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and ITPramod Yadav, CEO - Jubilant Pharma29 years of Industry ExperienceRajesh Srivastava, CEO life Sciences Ingredients29 years of Industry ExperiencePharmaceuticalsLife Sciences IngredientsDrug Discovery ServicesAjay KhannaChief -Strategic & Public Affairs37 years StructureMarcel J Velterop.

9 President -Drug Discovery Solutions28 years of Industry Institutional Institutions / MFs / and Indian of 30thSeptember2020 To acquire and maintain global leadership positionin chosen areas of businesses Tocontinuously create new opportunities for growth in our strategic businesses Tobe among the top 10 most admired companies to work for Tocontinuously achieve a return on capital of at least 10 points higher than the cost of capitalJubilant Vision6 Experienced Management team with high standards of corporate governanceArunSharmaExcutiveVice President & CFO26 years KazmiPresident & CEO Jubilant Therapeutics26 years of Industry ExperienceProprietary Drug DiscoveryPharmaceuticals SegmentEvolution of Jubilant PharmaRadiopharmaAllergy Therapy ProductsCMOA ctive Pharmaceutical ProductsSolid Dosage Formulations_____(1)

10 Revenue from operationsFY03FY04FY05FY06FY07FY08FY09FY 10FY11FY12FY13FY14FY15FY16FY17FY18 JLL acquired API business Nanjangud, Karnataka, IndiaAcquired Pharmaceutical Services Incorporated and PSI Supply (Belgium)Created R&D centrefor solid dosage formulationsAcquired a majority stake in CadistaHoldings Inc. (generics pharmaceutical company in the US) with a USFDA approved manufacturing facility for solid dosage formulationsAcquired HollisterStierLaboratories LLC in US (a CMO service provider)Acquired DraxisPharma Inc.